Results 221 to 230 of about 1,389,605 (343)

Location of Promoter and Operator Sites in the Biotin Gene Cluster of Escherichia coli

, 1972
P. Patrick Cleary, Allan Campbell, Robin Chang   +2 more
openalex   +1 more source

Understanding TERT Promoter Mutations: A Common Path to Immortality

Molecular Cancer Research, 2016
Robert J. A. Bell, H. T. Rube, Ana Xavier-Magalhães, B. Costa, A. Mancini, Jun S. Song, J. Costello   +6 more
semanticscholar   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Multiple regulators control the biosynthesis of brasilicardin in Nocardia terpenica. [PDF]

Appl Microbiol Biotechnol
Wolański M, Krawiec M, Nieselt K, Schwarz T, Dere D, Krismer B, Cano-Prieto C, Gross H, Zakrzewska-Czerwińska J.   +8 more
europepmc   +1 more source

In vivo transcription of rRNA operons in Escherichia coli initiates with purine nucleoside triphosphates at the first promoter and with CTP at the second promoter.

, 1979
Herman de Boer, Michio Nomura
openalex   +1 more source

Brian J. YOUNG, Promoters and Politicians. The North-Shore Railways in the History of Quebec, 1854-1885 [PDF]

, 1979
Albert Faucher
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

DNA hypomethylation modification promotes BST2 expression in cervical cancer by facilitating STAT1 binding to the promoter of BST2. [PDF]

Infect Agent Cancer
Wubuli R, Ainiwaer Z, Niyazi M, Han L.
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Susceptibility of RUNX1 promoter rs2071029 polymorphism to adjuvant chemotherapy-induced neutropenia in CRC. [PDF]

Biomark Med
Luo X, Wang H, Huang Z, Lin Z, Li C, Wang Q, Wei Y.   +6 more
europepmc   +1 more source